Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Rasha Magdy M Said; Tamer M. Ahmed; Rana Z. Abbas; Heba S. Agamy; Raed A. Shamkh; Basma S. M. Ali

doi:10.2478/fco-2024-0019

.blurhash-client-img { display: none !important; }

Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Forum of Clinical Oncology

AHEAD OF PRINT

By: Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh and Basma S. M. Ali

Open Access

|Mar 2026

Abstract

Background

Endocan is primarily presented as a soluble dermatan sulfate proteoglycan that is expressed in endothelial cells, as well as in serum and plasma. In acute leukemia patients, disease status was found to correlate with endocan levels as it was strongly expressed in untreated patients but decreased after chemotherapy. Furthermore, endocan levels were sensitive to recurrence, as indicated by an increase in levels during relapse. Notably, no significant change in endocan levels was observed before and after chemotherapy in patients who did not achieve remission.

Subjects and Methods

Our research team conducted a prospective study at Ain Shams University Hospitals, Clinical Hematology, and Stem Cell Transplant Unit. This study included 45 patients diagnosed with de novo acute leukemia. Endocan levels were measured before and at day 28 after chemotherapy induction.

Results

A high significant statistical correlation was found between the initial and post-induction endocan levels, with higher initial values observed. A nearly significant correlation existed between the initial endocan levels in responders and non-responders (AML) patients, with non-responder patients showing higher values. Furthermore, a significant positive correlation was found between initial endocan and both lactate dehydrogenase and the initial bone marrow evaluation.

Conclusion

Pre-induction endocan levels are significantly elevated in acute leukemia patients compared to post-induction levels, showing a near significant correlation with remission status in AML, but there was no significant correlation in ALL patients. Endocan level has a potential prognostic significance in acute leukemia.

References

Anitha GRJ, Chandraprabha VR, Padmakumar D, et al. (2024). Exploring the Prevalence and Prognostic Impact of Wilms Tumor 1 Exon 7 Mutation Status with Combinations of FLT3-ITD and NPM1 Mutations as Potential Molecular Biomarkers in Acute Myeloid Leukemia Patients with Normal Cytogenetics. Asian Pac J Cancer Prev, 25(10):3463–3470.
Search in Google Scholar Back to article
De Angelis R, Minicozzi P, Sant M, et al. (2015). Survival variations by country and age for lymphoid and myeloid malignancies in europe 2000–2007: Results of eurocare-5 population-based study. Eur J Cancer, 51(15):2254–68.
Search in Google Scholar Back to article
Terwilliger T., & Abdul-Hay, M. J. B. C. J. (2017). Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal, 7:577.
Search in Google Scholar Back to article
Paul S., Kantarjian H., & Jabbour E. J. (2016). Adult acute lymphoblastic leukemia. 91:1645–1666.
Search in Google Scholar Back to article
Reikvam H, Hatfield KJ, Wendelbo Ø, et al. (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules, 12(4):492.
Search in Google Scholar Back to article
Hatfield KJ, Lassalle P, Leiva RA, et al. (2011). Serum levels of endotheliumderived endocan are increased in patients with untreated acute myeloid leukemia. Hematology, 16(6):351–356.
Search in Google Scholar Back to article
Huang X, Chen C, Wang X, et al. (2016). Prognostic value of endocan expression in cancers: evidence from meta-analysis. OncoTargets and Therapy, 9:6297–6304.
Search in Google Scholar Back to article
Lin LY, Yeh YC, Chu CH, et al. (2017). Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors. Medicine, 96(41):8262.
Search in Google Scholar Back to article
Yang YC, Pan KF, Lee WJ, et al. (2020). Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer. Cancer Res, 80:3292–3304.
Search in Google Scholar Back to article
El Behery MM, Seksaka MA, Ibrahiem MA, et al. (2013). Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet, 288:1371–1376.
Search in Google Scholar Back to article
Hendrix MJ, Seftor EA, Hess AR, et al. (2003). Molecular plasticity of human melanoma cells. Oncogene, 22:3070–3075.
Search in Google Scholar Back to article
Arslan B, Onuk Ö, Hazar İ, et al. (2017). Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. Tumori, 103(2):204–208.
Search in Google Scholar Back to article
Steiner N, Hajek R, Sevcikova, et al. (2018). The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research, 38(9):5087–5092.
Search in Google Scholar Back to article
Roccaro AM, Hideshima T, Raje N, et al. (2006). Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res, 66(1):184–191.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/fco-2024-0019 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Submitted on: Aug 2, 2025

Accepted on: Nov 4, 2025

Published on: Mar 24, 2026

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Related subjects:

Haematology, oncology

© 2026 Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh, Basma S. M. Ali, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT